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Abstract
Mycobacterium avium ssp. hominissuis, hereafter referred to as M. avium, forms biofilm, a property that, in mice, is associated with lung
infection via aerosol. As M. avium might co-inhabit the respiratory tract with other pathogens, treatment of the co-pathogen-associated
infections, such as in bronchiectasis, would expose M. avium to therapeutic compounds that may have their origin in other organisms
sharing the natural environments. Incubation of M. avium with two compounds produced by environmental organisms, streptomycin and
tetracycline, in vitro at subinhibitory concentrations increased biofilm formation in a number of M. avium strains, although exposure to
ampicillin, moxifloxacin, rifampin and trimethoprim–sulphamethoxazole had no effect on biofilm formation. No selection of genotypically
resistant clones was observed. Although incubation of bacteria in the presence of streptomycin upregulates the expression of biofilm-
associated genes, the response to the antibiotics had no association with the expression of a regulator (LysR) linked to the formation
of biofilm in M. avium. Biofilms are composed of planktonic and sessile bacteria. Whereas planktonic M. avium is susceptible to clarithro-
mycin and ethambutol (clinically used antimicrobials), sessile bacteria are at least three-fold to four-fold more resistant to antibiotics.
The sessile phenotype, however, is reversible, and no selection of resistant clones was observed. Mice infected through the airway with
both phenotypes were infected with a similar number of bacteria, demonstrating no phenotype advantage. M. avium biofilm formation is
enhanced by commonly used compounds and, in the sessile bacterial phenotype, is resistant to clarithromycin and ethambutol, in a
reversible manner.
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Introduction
Biofilm formation is an approach used by a number of organ-
isms to survive under conditions of nutrient depletion [1].
Mycobacterium avium ssp. hominissuis, hereafter referred to as
M. avium, is an environmental bacterium that commonly
causes infection in individuals with chronic lung infection and
AIDS [2–4]. One of the characteristics of M. avium is the abil-
ity to form biofilm in the environment [5]. Several genes have
been linked with the ability to develop biofilm on both poly(vi-
nyl carbonate) (PVC) and plastic surfaces. M. avium mutants
deficient in those genes are impaired in biofilm formation in vi-
tro [6]. More recently, it has been shown that M. avium lung
infection in mice appears to be greatly dependent on the abil-
ity to colonize and establish biofilm on the surface of bronchial
cells [6]. This finding offers, at least partially, a possible expla-
nation for the difficulty in treating M. avium lung infection
[7,8], which is frequently unsuccessful [9].
Although the presence of biofilm could be the explanation
for many of the clinical aspects of M. avium complex lung infec-
tion, other factors may participate in and influence the forma-
tion and maintenance of biofilm, and the response to therapy.
M. avium is an environmental organism that exists in the pres-
ence of other bacteria, both in the environment outside the
host and in the host. For example, in both soil and water,
M. avium shares the habitat with many other organisms, poten-
tially forming complex colonies. In individuals with chronic lung
disease, many pathogens, such as Pseudomonas aeruginosa, Burk-
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holderia cepacia and Staphylococcus aureus, can be found co-hab-
iting in the airways. It is common for these patients to have
many episodes of infection, for which antibiotics are often pre-
scribed. There is a possibility that some of the environmental
microorganisms that produce natural antibacterial molecules
used in therapy for humans share the soil with M. avium.
Assuming that M. avium will have been in contact with some of
the same antibacterial molecules before, it is likely that the
bacterium will has developed defence mechanisms, which can
certainly be triggered by the presence of the same or similar
antimicrobial molecules found in the environment.
The biofilm structure is composed of at least two popula-
tions of microorganisms, planktonic and sessile. Sessile bacte-
ria form the biofilm, and planktonic organisms occasionally
detach (in both the pre-biofilm phase and the post-biofilm
phase). A number of studies investigating a large number of
pathogens, including Mycobacterium abscessus, have estab-
lished that planktonic and sessile subpopulations have differ-
ent susceptibilities to antibiotics [10]. Biofilm resistance to
antibiotics has been attributed to at least two main factors.
One is that biofilm creates a barrier against the penetration
of antibiotics; and the other is that bacteria in the biofilm
are not in the replicating state, and are therefore resistant
to the majority of antibiotics.
In this study, we first examined whether several antibiotics
that are commonly used to treat infections in patients with
cystic fibrosis and other chronic lung diseases have any effect
on the ability of M. avium to form biofilm. In addition, we
evaluated the susceptibility of planktonic and sessile subpopu-
lations to antibiotics that are frequently used to treat lung
M. avium infection.
Materials and Methods
Bacteria
M. avium strains 101, 104 and A5 (kindly provided by
K. Eisenach, University of Arkansas, Little Rock, USA) were
used in the reported experiments. They were isolated from
the blood of an AIDS patients. Strains 3362-33 and 3362-34
are M. avium strains isolated from the lungs of individuals
with pulmonary pathology. They were kindly provided by
R. Wallace (Tyler, TX, USA). Bacteria were grown on Mid-
dlebrook 7H10 agar supplemented with oleic acid, albumin,
dextrose and catalase for 10 days at 37C, harvested and
used to establish a suspension of 5 · 108 CFU/mL. The sus-
pension was then used to seed a PVC 96-well plate, as
described previously [5,11,12]. The plate was kept at room
temperature for 14 days. After this period, biofilm had devel-
oped on the surface of the walls. The biofilm-impaired
strains 5G4 (in which MAV_3209 hypothetical membrane
protein has been inactivated) and 6H9 (in which SucA has
been inactivated) were cultured in agar plates in the pres-
ence of 200 mg/L kanamycin. The strains have been previ-
ously described [6,12] and are transposon mutants of
strain A5. M. avium clone 8G12 was obtained by screening a
transposon library for clones associated with increased ability
to form biofilm on PVC. Clone 8G12 was selected because
it has an eight-fold greater ability to form biofilm (relative
increase as compared with the parent strain A5) than the
wild-type strain A5. Sequencing of the inactivated gene
determined that it is MAV_2151, which encodes a transcrip-
tion regulator of the LysR family (data not shown).
Antibiotics
Streptomycin and tetracycline were initially isolated from
environmental fungi and bacteria. Ampicillin, rifampin, moxi-
floxacin and trimethroprim–sulphamethoxazole were also
used. All of the compounds, with one exception, were pur-
chased from Sigma Chemicals (St Louis, MO, USA). Moxi-
floxacin was obtained from Bayer (West Haven, CT, USA).
Different concentrations were obtained by dilution in Hank’s
balanced salt solution (HBSS). Clarithromycin was provided
by Abbott Laboratories (Chicago, IL, USA) and ethambutol
was purchased from Sigma.
Antibiotic susceptibility testing was performed with both
planktonic and sessile phenotypes, as previously described,
with a broth microdilution method [11]. Briefly, 1 · 105 bac-
teria were seeded in 0.3 mL of 7H9 Middlebrook broth with
oleic acid, albumin, dextrose and catalase in a 96-well micro-
titre plate (Falcon, VWR, West Chester, PA, USA). The num-
ber of bacteria for the inoculum was established by using a
turbidity method, and confirmed by plating onto 7H10 agar.
The concentrations of clarithromycin and ethambutol used
ranged from 0.125 to 128 mg/L.
Biofilm assays and phenotypes
For the assays, we used three strains of M. avium isolated
from blood of AIDS patients (101, 104, and A5) and two
strains isolated from lung infection (3362-33 and 3362-34).
Bacteria were grown on Middlebrook 7H10 agar plates, and
1 · 107 bacteria in 0.3 mL of HBSS were then seeded in
wells of 96-well PVC plates. Two hours after seeding,
bacteria were exposed to either tetracycline or streptomycin
at 0.5, 1 or 2 mg/L (MICs >128 and 8 mg/L, respectively),
ampicillin 10 mg/L, moxifloxacin 1 mg/L, trimethoprim–
sulphamethoxazole 3 mg/L or rifampin 1 mg/L (subinhibitory
concentrations). Antibiotics were added again at day 7, and
PVC plates were followed for 14 days. Biofilm formation was
then quantified as previously reported [5,12], by measuring
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the amount of biofilm by staining it with crystal violet and
using the intensity of the staining to determine the exact bio-
film mass, by means of spectrophotometry.
To determine whether the phenotype was temporary or
permanent, sessile bacteria were passed on 7H10 agar plates
twice, and the MICs of both clarithromycin and ethambutol
were determined.
To obtain both subpopulations, PVC plates with M. avium
biofilm were allowed to remain at rest for 14 days. Then, the
supernatant was removed and centrifuged at 4000 g for
20 min at 4C to collect the bacterial pellet. The pellet, com-
posed of planktonic bacteria, was washed at 4C with HBSS,
passed through a 24-gauge needle ten times and resuspended
in fresh HBSS. The concentration was adjusted to
5 · 107 CFU/mL. The biofilm, composed of a sessile popula-
tion of bacteria, was then removed with a cotton swab and
resuspended in HBSS at 4C. The bacteria were spun down
as described above, and then passed through a 24-gauge nee-
dle ten times to disperse them in the suspension; the concen-
tration was then adjusted to 5 · 107 CFU/mL. Both
subpopulations were maintained at 4C for up to 3 days
before the assays, in order to conserve the phenotype. Bacte-
ria were then placed in 7H9 broth suspension with different
concentrations of antibiotics, and plated for quantification
after 48 h. The bacterial concentration in the inoculum was
determined by plating the suspensions onto 7H10 agar.
To determine whether clones of planktonic and sessile bac-
teria were resistant to 20 mg/L clarithromycin or ethambutol,
bacterial suspensions of 108 CFU/mL were plated onto 7H10
agar containing either clarithromycin or ethambutol. The same
inoculum was plated onto 7H10 agar without antibiotics.
Colonies obtained from plates with antibiotics were addition-
ally tested individually for susceptibility, as described above.
Mouse experiments
Female C57BL/6 mice, weighing 20 g, were purchased from
Jackson Laboratory (West Grove, PA, USA). After 1 week of
acclimation, mice were infected with 108 bacteria delivered
to the nostrils in 0.2 mL of HBSS. Twelve mice were used
per time-point. Mice were harvested at day 7 and at 5 weeks
following infection. Lungs were removed, homogenized,
diluted and plated onto 7H11 agar containing trimethoprim–
sulphamethoxazole, polymyxin B, carbenicillin and amphoteri-
cin B, as previously reported [6]. Quantification of CFUs was
performed after 14 days.
Biofilm-related genes
As exposure to streptomycin and tetracycline resulted in
increased biofilm formation, it was important to determine
whether the antibiotics triggered the expression of biofilm-
related genes. Both guaB2 and gtf were selected [12]. Those
genes are involved in glycopeptolipid synthesis and synthesis
of lipoarabinomannan, respectively. Strain 104 was exposed
to 1 mg/L streptomycin or 1 mg/L tetracycline for 2 h, and
RNA purification and cDNA synthesis were performed as
previously described [13]. The cDNA was amplified using
the following primers: GuaB2 F, 5¢-TCA CCT GCC GCC
CCG ACA ACA CGC TGC CCC-3¢; GuaB2 R, 5¢-GGC ACC
CGG CCC TCG ATG CCC TCG GGC ACC-3¢; Gtf F, 5¢-ATG
GAG GGC GCC GAC GTG CCC-3¢; and Gtf R, 5¢-AGG
ATC GCG GTG ATG CTG CCC-3¢.
Real-time PCR was carried out as previously described
[12]. Briefly, quantitative fluorogenic amplification of cDNA
was performed using the iCycler (Bio-Rad) and SYBR green
technology (Bio-Rad, Hercules, CA, USA), according to the
method previously described [12].
Statistical analysis
Experiments were repeated at least three times, and the
results are expressed as a mean ± standard deviation. The
comparisons among experimental groups were performed
with ANOVA and Student’s t-test when appropriate. A
p-value of <0.05 was considered to be statistically significant.
Results
Antibiotics and biofilm
It was observed that exposure to streptomycin at subinhibi-
tory concentrations resulted in increased M. avium biofilm
formation. In fact, incubation in the presence of antimicrobial
molecules produced by environmental microorganisms may
impact on the formation of biofilm by other environmental
bacteria. AIDS-derived M. avium strains placed in contact
with tetracycline were induced to produce significantly more
biofilm, although the significance of the increase in biofilm
formation related to tetracycline exposure may be under-
stated in relation to the MIC of tetracycline and the concen-
tration of the antibiotic that M. avium was exposed to.
Incubation with streptomycin at 0.5 mg/L also induced AIDS-
derived M. avium to produce increased amounts of biofilm.
When pulmonary strains of M. avium were exposed to either
tetracycline or streptomycin at all tested concentrations,
both strains showed significant increases in biofilm produc-
tion (Tables 1 and 2). Exposure to ampicillin, moxifloxacin or
trimethoprim–sulphamethoxazole did not result in any
change in biofilm formation (Table 3). The use of rifampin
was associated with a decrease in the biofilm mass of
10% ± 6% (p >0.05). When mutants impaired in biofilm
formation—6H9 and 5G4—and 8G12, a mutant that forms
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an increased amount of biofilm as compared with the wild-
type bacterium, were exposed to streptomycin and tetra-
cycline (data not shown), the 6H9 and 5G4 mutants did not
produce increased amounts of biofilm (Table 1). Exposure of
the mutant that produces a high amount of biofilm to strep-
tomycin resulted in a small, but consistent, increase in bio-
film formation (Table 1).
Biofilm-related genes
In order to examine whether exposure to streptomycin
or tetracycline induces biofilm-related gene expression in
M. avium, 104 biofilm was exposed to 1 mg/L of each antibi-
otic, and the expression of guaB2 and gtf was monitored. As
shown in Fig. 1, in agreement with previously published data,
both genes were expressed during biofilm formation. Gene
expression was, however, significantly greater when antibiot-
ics were applied to biofilms.
We established the MICs of clarithromycin and ethambu-
tol for strains 104, 101, A5, 3362-33 and 3362-34, and the
5G4 and 6H9 mutants. All of the strains had an MIC of
2 mg/L for clarithromycin, except for 3362-33, for which the
MIC was 4 mg/L. Similarly, the MICs of ethambutol did not
vary significantly, with all of the strains, except for 101 and
A5 (MIC 2 mg/L), being inhibited at 1 mg/L.
TABLE 1. Effect of streptomycin exposure on biofilm for-
mation by Mycobacterium avium strains
Biofilm formation (OD ± SD)a
M. avium
strain No antibiotic
Streptomycin (mg/L)b
0.5 1 2
104 0.236 ± 0.026 0.156 ± 0.032c 0.534 ± 0.046c 0.549 ± 0.041c
101 0.243 ± 0.029 0.584 ± 0.041c 0.563 ± 0.041c 0.545 ± 0.065c
A5 0.266 ± 0.041 0.668 ± 0.036c 0.681 ± 0.044c 0.685 ± 0.048c
3362-33 0.222 ± 0.032 0.508 ± 0.016c 0.628 ± 0.023c 0.699 ± 0.037c
3362-34 0.278 ± 0.048 0.497 ± 0.039c 0.548 ± 0.062c 0.591 ± 0.056c
A5 0.286 ± 0.045 0.647 ± 0.051d 0.670 ± 0.041d
8G12 0.592 ± 0.051 0.732 ± 0.056e 0.744 ± 0.026e
5G4 0.159 ± 0.040a 0.194 ± 0.024e 0.211 ± 0.034e
6H9 0.123 ± 0.067a 0.143 ± 0.042e 0.173 ± 0.028e
OD, optical density; SD, standard deviation.
aBiofilm mass was measured by staining the biofilm with crystal violet and deter-
mining the OD of the crystal violet by spectrophotometry [5,11].
bThe results are the means of three independent experiments.
cp <0.05 as compared with biofilm without exposure to antibiotic.
dp <0.05 as compared with A5 without exposure to antibiotic.
ep >0.05 as compared with the mutant without exposure to antibiotic.
TABLE 2. Effect of tetracycline exposure on biofilm forma-
tion by Mycobacterium avium strains
Biofilm formation (OD ± SD)a
M. avium
strains No antibiotic
Tetracycline (mg/L)b
0.5 1 2
104 0.256 ± 0.026 0.310 ± 0.042 0.316 ± 0.031c 0.350 ± 0.017c
101 0.243 ± 0.029 0.314 ± 0.046 0.327 ± 0.023c 0.329 ± 0.036c
A5 0.266 ± 0.041 0.312 ± 0.022 0.336 ± 0.039c 0.342 ± 0.028c
3362-33 0.222 ± 0.032 0.371 ± 0.033c 0.384 ± 0.040c 0.388 ± 0.019c
3362-34 0.206 ± 0.057 0.423 ± 0.042c 0.457 ± 0.040c 0.481 ± 0.050c
OD, optical density; SD, standard deviation.
aThe biofilm mass was measured by staining the biofilm with crystal violet and
determining the OD of the crystal violet by spectrophotometry [5,11].
bThe results represent three independent experiments.
cp <0.05 as compared with biofilm not exposed to antibiotic.
TABLE 3. Biofilm formation among
Mycobacterium avium strains exposed
to ampicillin, moxifloxacin, rifam-
pin and trimethoprim–sulphameth-
oxazole (TMP-SMX)
Biofilm formation (% increase/decrease) at 7 days
M. avium strain No antibiotic
Ampicillin
(10 lg/L)
Moxifloxacin
(1 lg/L)
TMP-SMX
(3 lg/L)
Rifampin
(1 lg/L)
104 0.271 ± 0.032 1 ± 0.3 0.1 ± 0.02 0.2 ± 0.03 )10 ± 6a
101 0.266 ± 0.049 0.4 ± 0.1 0.2 ± 0.02 0.3 ± 0.03 )7 ± 3a
A5 0.296 ± 0.057 0.3 ± 0.07 0.2 ± 0.05 0.2 ± 0.08 )9.2 ± 3a
3362-33 0.274 ± 0.037 0.2 ± 0.03 0.2 ± 0.1 0.2 ± 0.05 )10.1 ± 4a
3362-34 0.230 ± 0.025 0.1 ± 0.06 0.1 ± 0.09 0.2 ± 0.06 )9.6 ± 2a
ap <0.05 as compared with biofilm formation without antibiotic exposure.
Results represent the mean percentage increase in biofilm formation of two different experiments.
FIG. 1. Real-time PCR showing the fold increase, as compared with
the bacteria not exposed to antibiotics, in the expression of guaB2
and gtf. Biofilm, no antibiotic treatment; Strep, in the presence of
1 mg/L streptomycin; Tc, in the presence of 1 mg/L tetracycline.
p <0.05 for the comparison between biofilm and biofilm exposed
to streptomycin. The assay was run as described in Materials and
Methods.
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Planktonic and sessile subpopulations
To examine the MICs of the compounds for two subpopula-
tions of M. avium in biofilm, planktonic and sessile, both pop-
ulations were purified and bacteria were kept at 4C until
the assay. In addition, the two populations were cultured in
7H9 broth for two passages of 10 days before determination
of MICs. Table 4 shows that sessile bacteria had MICs of
clarithromycin five-fold greater than those of the planktonic
bacteria, and an MIC of ethambutol four-fold greater than
for the planktonic bacteria. Sessile bacteria passed twice in
7H9 broth underwent a reversion of the phenotype, and had
MICs similar to those of planktonic M. avium.
To determine whether planktonic phenotype and the bio-
film (sessile) phenotype would be able to infect mice equally,
mice were exposed to bacteria (planktonic and sessile) via
aerosol, and harvested at 7 days and 5 weeks after infection.
The results (Table 5) show that the levels of infection with
both strains were similar with regard to the number of CFUs
in lungs and spleen, suggesting that both phenotypes are able
to establish infection equally.
Sessile bacteria showed increased resistance to antibiotics.
To investigate whether the phenotype is stable and repre-
sents the selection of a subpopulation of M. avium, sessile
and planktonic clones were plated on 7H10 agar or 7H10
agar with clarithromycin at 20 mg/L, and the percentage of
resistant colonies was quantified. As shown in Fig. 2, the
resistant phenotype for clarithromycin was observed in the
first passage, but was lost in subsequent passages.
Discussion
M. avium is an environmental pathogen that causes lung dis-
ease in patients with underlying pulmonary conditions [14].
M. avium is believed to be acquired primarily from the envi-
ronment, most frequently from soil and water sources
[15,16]. It has been demonstrated that the bacterium can be
isolated from biofilms on sauna walls and in urban water sys-
tems [15,16]. More recently, it has been shown that M. avi-
um can be commonly cultured in large amounts from
household shower heads [17]. Therefore, individuals are
exposed frequently to the bacterium, and those with risk fac-
tors may develop disease.
M. avium’s ability to form biofilm appears to be necessary
for it to cause pulmonary infection in mice. Mutant strains
with deficiencies in developing biofilm had impaired ability to
cause disease when delivered to the mice by aerosol [6].
TABLE 4. MICs of clarithromycin and ethambutol for plank-
tonic and sessile subpopulations of Mycobacterium avium
Subpopulation of M. avium 104
MIC (mg/L)
Clarithromycin Ethambutol
Planktonica 4 2
Sessilea 64b 16b
Planktonicc passed in medium 4 2
Sessilec passed in medium 4 2
aPlanktonic and sessile subpopulations were collected as described in Materials
and Methods. Bacteria were kept at 4C to maintain the phenotype, and then
placed in 7H9 broth with different concentrations of antibiotics for 48 h. The
inoculum was determined by plating onto 7H10 agar without antibiotics.
bp <0.05 as compared with the the planktonic subpopulation.
cPlanktonic and sessile subpopulations were cultured twice on 7H10 agar at
37C for 10 days before the determination of MIC.
TABLE 5. Infection of C57BL/6
mice with planktonic and sessile
Mycobacterium avium strain 104
Bacteriaa
CFU/lung and spleen
Spleenb Lungb
Day 7 Week 5 Day 7 Week 5
Planktonic (6.1 ± 1) · 104 (3 ± 2) · 107 (2 ± 0.9) · 105 (7.1 ± 1.8) · 108
Sessile (8.7 ± 0.7) · 104 (5.1 ± 0.8) · 107 (3.3 ± 1.1) · 105 (9.6 ± 0.6) · 108
aInoculum: planktonic, 1.4 · 108; sessile, 1.6 · 108.
bp-values were not significant between the experimental groups at all time-points.
FIG. 2. Selection of resistant and susceptible bacteria. Planktonic
and sessile subpopulations were plated onto 7H10 agar. The 7H10
agar plates contained 20 mg/L clarithromycin. The figure shows how
many of the original colonies were resistant to antibiotics.
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Environmental bacteria are likely to compete with other
bacteria for nutrients and survival. Many bacteria are known to
produce antimicrobials that are lethal against other environ-
mental organisms. Natural evolution would support the devel-
opment of defence mechanisms, which often involve biofilm
formation, in order to defend against environmental bacte-
rium-generated products. The current opinion is that many of
these products released into the environment work as signal-
ling molecules for metabolic pathways in other organisms [18].
We show in this study that M. avium responds with an
increase in biofilm formation when exposed to streptomycin
and tetracycline at subinhibitory concentrations, but not
when incubated with ampicillin, trimethoprim–sulphamethox-
azole, moxifloxacin or rifampin. Tetracycline had a less
accentuated effect against some of the strains tested. The
finding was substantiated by the enhanced expression of
M. avium biofilm-related genes upon exposure to antibiotics.
Interestingly, ampicillin is derived from Penicillium and rifam-
pin from Nocardia. The importance of the observation is that
many patients with chronic lung conditions are treated with
antibiotics, such as aminoglycosides or tetracyclines, for
infections caused by many pathogens [19]. Therefore, there
is a possibility that, in cases where M. avium is colonizing an
individual receiving antibiotic, either for prophylaxis or for
treatment, this could potentially result in the production of
increased amounts of biofilm and further establishment of
the infection.
In terms of existence and evolution, host infection is a
consequence of M. avium survival in the environment. M. avium
utilizes many of the features necessary to overcome environ-
mental challenges and to infect and persist in the host. Among
them are genes associated with amoebal invasion [20] and genes
linked to biofilm formation [12]. Here we show that an iatro-
genic action, antibiotic use, reproduces the environmental
conditions of mixed biofilms, in which the bacterial structure
becomes more resistant to damage inflicted from outside.
Therefore, special care should be taken when a decision is made
to administer antimicrobials to patients with chronic lung condi-
tions in which the presence of M. avium is a possibility. Future
studies will be needed to determine whether the effect of anti-
biotics in vivo-formed biofilm follows similar dynamics.
Once in a particular environment, biofilms are composed
of at least two populations of bacteria, planktonic and sessile.
The results obtained confirmed what many other groups
working with different pathogens have already observed. The
sessile phenotype is resistant to antibiotics, but the plank-
tonic bacteria are susceptible. Such resistance has been
described as being associated with the organization of the
biofilm, but when biofilm was dispersed, bacteria still
expressed a significant resistant phenotype. The mechanism
for resistance (or reduced susceptibility) is unknown; how-
ever, the presence of biofilm matrix and its impact on bacte-
rial phenotype, e.g. upregulation of bacterial antibiotic pump
expression, could be factors influencing the phenotype.
Many studies in other systems have looked at planktonic
phenotypes of pathogens. Recent work has evaluated the
susceptibility of the planktonic population form of M. absces-
sus and determined that it is susceptible to antibiotics [10].
There is, however, no information on the detachment of
planktonic bacteria from biofilms and the mechanisms of that
detachment.
In summary, M. avium forms increasing amounts of biofilm
in the presence of antibiotics such as streptomycin and tetra-
cycline, which stimulate biofilm-related gene expression in
the bacterium. Once formed, biofilms are composed of two
distinct populations of bacteria: sessile, the more resistant
phenotype; and planktonic, a susceptible phenotype. The role
of clinically used antibiotics in stimulating signal transduction
and metabolic pathways in bacteria is not well known, and
should be studied further in mycobacteria.
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